{"id":"detrol-la","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"5-7","effect":"Headache"},{"rate":"15-20","effect":"Constipation"},{"rate":"2-4","effect":"Dizziness"},{"rate":"1-2","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":{"setId":"d7274947-4f88-47ee-a39f-bd5ac46fcf8d","title":"DETROL LA (TOLTERODINE TARTRATE) CAPSULE, EXTENDED RELEASE [VIATRIS SPECIALTY LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Detrol LA (tolterodine tartrate extended-release) selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking acetylcholine-mediated contractions, it decreases the frequency and urgency of urination and increases bladder capacity, providing symptomatic relief of overactive bladder.","oneSentence":"Detrol LA is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary muscle contractions and urinary urgency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:27.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":"Interstitial Cystitis","enrollment":26},{"nctId":"NCT00293839","phase":"PHASE3","title":"Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Urinary Incontinence","enrollment":790},{"nctId":"NCT00966004","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07-24","conditions":"Urinary Bladder, Overactive","enrollment":1139},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT01488578","phase":"","title":"Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Overactive Bladder","enrollment":11157},{"nctId":"NCT00230789","phase":"PHASE4","title":"Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-10","conditions":"Urinary Incontinence","enrollment":417},{"nctId":"NCT00411437","phase":"PHASE4","title":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Memory, Cognition","enrollment":220},{"nctId":"NCT00147654","phase":"PHASE4","title":"Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Urinary Incontinence","enrollment":830},{"nctId":"NCT00282932","phase":"PHASE4","title":"Detrol LA In Men With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-01","conditions":"Overactive Bladder (OAB)","enrollment":600},{"nctId":"NCT00143481","phase":"PHASE4","title":"Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-03","conditions":"Urinary Incontinence","enrollment":400},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT01741454","phase":"PHASE4","title":"Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2012-11","conditions":"Ureteral Obstruction","enrollment":181},{"nctId":"NCT01829425","phase":"NA","title":"Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2013-04-22","conditions":"Urinary Incontinence, Urge","enrollment":165},{"nctId":"NCT02436889","phase":"PHASE4","title":"Treatment of Incontinence Without Memory Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-02","conditions":"Urge Incontinence, Urinary Incontinence, Urge","enrollment":23},{"nctId":"NCT01314872","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-31","conditions":"Urinary Bladder, Overactive","enrollment":1395},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":"Overactive Bladder, Overactive Urinary Bladder","enrollment":4},{"nctId":"NCT00465894","phase":"NA","title":"Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-04","conditions":"Overactive Bladder","enrollment":58},{"nctId":"NCT00323635","phase":"PHASE4","title":"A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2006-04","conditions":"Urinary Incontinence","enrollment":19},{"nctId":"NCT01175382","phase":"PHASE2, PHASE3","title":"Combined Behavioral and Drug Treatment of Overactive Bladder in Men","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-07","conditions":"Overactive Bladder, Lower Urinary Tract Symptoms","enrollment":204},{"nctId":"NCT00780832","phase":"NA","title":"Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder","status":"TERMINATED","sponsor":"IWK Health Centre","startDate":"2008-05","conditions":"Overactive Bladder","enrollment":8},{"nctId":"NCT01356355","phase":"PHASE2","title":"Study of Herbmed Plus in Ureteral Stent Discomfort","status":"COMPLETED","sponsor":"Dr .S.B.PATANKAR","startDate":"2012-04","conditions":"Ureteral Stent Discomfort","enrollment":140},{"nctId":"NCT00939120","phase":"PHASE4","title":"Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Siami, Paul F., M.D.","startDate":"2009-07","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":46},{"nctId":"NCT00454740","phase":"PHASE3","title":"Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Urinary Bladder, Overactive","enrollment":441},{"nctId":"NCT01089751","phase":"PHASE4","title":"Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Overactive Bladder","enrollment":322},{"nctId":"NCT00703703","phase":"PHASE1","title":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Healthy","enrollment":117},{"nctId":"NCT00553657","phase":"PHASE1","title":"The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Overactive Bladder","enrollment":55}],"_emaApprovals":[],"_faersSignals":[{"count":1177,"reaction":"DRUG INEFFECTIVE"},{"count":453,"reaction":"DRY MOUTH"},{"count":397,"reaction":"FALL"},{"count":369,"reaction":"DIZZINESS"},{"count":355,"reaction":"FATIGUE"},{"count":344,"reaction":"DIARRHOEA"},{"count":323,"reaction":"CONSTIPATION"},{"count":323,"reaction":"NAUSEA"},{"count":323,"reaction":"PAIN"},{"count":322,"reaction":"HEADACHE"}],"_approvalHistory":[{"date":"20051020","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20040115","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20110920","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20011217","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20140728","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20010427","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20080911","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20070316","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20001222","type":"ORIG","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20050714","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20040414","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20030721","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20180713","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20100105","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20010921","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"},{"date":"20120801","type":"SUPPL","sponsor":"UPJOHN","applicationNumber":"NDA021228"}],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Detrol LA","genericName":"Detrol LA","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Detrol LA is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary muscle contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}